US Pharma MarketingExclusive: Akeso pushes back on ASCO questioning of lung cancer drug
Akeso CEO Michelle Xia tells Endpoints the scrutiny of Chinese vs. Western patient data for ivonescimab is overblown, with the FDA deciding on US approval by Nov. 14. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act…
Akeso leadership is pushing back on some of the questions about its next-generation cancer drug raised earlier this month at the annual American Society of Clinical Oncology meeting.
In an exclusive interview with Endpoints News ...
Source: Endpoints News